Targeted therapies in head and neck cancer: past, present and future.

Détails

ID Serval
serval:BIB_0E7D206021E9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Targeted therapies in head and neck cancer: past, present and future.
Périodique
Reviews on Recent Clinical Trials
Auteur(s)
Rapidis A.D., Vermorken J.B., Bourhis J.
ISSN
1574-8871 (Print)
Statut éditorial
Publié
Date de publication
2008
Volume
3
Numéro
3
Pages
156-166
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
Head and neck cancers remain a significant health problem globally. The addition of chemotherapy to radiotherapy for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has led to improvements in locoregional disease control and in survival, but is associated with substantial acute and late toxicities. In recurrent and/or metastatic SCCHN, there have been no improvements in survival, despite the manipulation of standard therapeutic regimens and the introduction of newer cytotoxic agents. Over the last decade, targeted therapies have been increasingly used in a range of solid tumor types. This article discusses the clinical evidence for the use of a number of targeted agents in the treatment of locoregionally advanced and recurrent and/or metastatic SCCHN. The article focuses on the epidermal growth factor receptor (EGFR) inhibitors, for which the majority of clinical information is available. These include the monoclonal antibody (MAb) cetuximab and the tyrosine kinase inhibitors, erlotinib and gefitinib. Clinical data for the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, are also presented.
Mots-clé
Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Chemotherapy, Adjuvant/trends, Clinical Trials as Topic, Combined Modality Therapy/trends, Head and Neck Neoplasms/drug therapy, Humans, Receptor, Epidermal Growth Factor/administration & dosage, Receptor, Epidermal Growth Factor/antagonists & inhibitors, Treatment Outcome, Vascular Endothelial Growth Factor A/administration & dosage, Vascular Endothelial Growth Factor A/antagonists & inhibitors
Pubmed
Création de la notice
01/12/2014 17:24
Dernière modification de la notice
20/08/2019 12:35
Données d'usage